Giant Biogene

Giant Biogene (巨子生物, 02367.HK) is a China-based leader in professional skin care products built on bioactive ingredients, listed on the Hong Kong Stock Exchange main board in November 2022 as the "first collagen stock" . The company specializes in recombinant collagen, having developed and mass-produced 33 distinct types through a synthetic biology platform integrating biotechnology, biochemistry, and bioengineering . Its two flagship brands, Comfy (可复美) and Collgene (可丽金), ranked third and fourth respectively in China's professional skin care market by retail sales in 2021 . Gaorong Ventures participated in the company's only funding round to date in October 2021 . In 2024, Giant Biogene secured a national invention patent for recombinant human type XVII collagen, which the company claims shows hair follicle repair and regeneration properties exceeding minoxidil, extending its collagen portfolio beyond types I and III .